Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity

Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity

Collection:
Health Policy and Services Research
Series Title(s):
ASPE issue brief
Author(s):
Kolbe, Allison, author
Contributor(s):
United States. Department of Health and Human Services. Office of Science and Data Policy, issuing body.
Publication:
Washington, DC : Office of the Assistant Secretary for Planning and Evaluation, Office of Science & Data Policy, December 2021
Language(s):
English
Format:
Text
Subject(s):
Antibodies, Monoclonal, Humanized -- therapeutic use
COVID-19 Drug Treatment
Healthcare Disparities
Social Vulnerability
Urban Population
Vulnerable Populations
United States
Genre(s):
Technical Report
Abstract:
Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Between November 2020 and March 2021, the number of monoclonal antibody doses administered per 100,000 COVID-19 diagnoses at the county level varied significantly across the country. Counties with high social vulnerability in terms of socioeconomic status, racial or ethnic minority population, or housing and transportation tended to use monoclonal antibodies at a lower rate during this period compared with other counties. Given the disproportionate impact of COVID-19 on specific populations, including racial and ethnic minorities, ensuring equitable distribution and accessibility of these drugs and other therapeutics is a critical tool in combatting COVID-19.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)
Extent:
1 online resource (1 PDF file (15 pages))
Illustrations:
Illustrations
NLM Unique ID:
9918538381206676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918538381206676